PeerView Internal Medicine CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share





Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape


Go online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and investigational targeted therapies in newly diagnosed patients and those with acquired resistance. Upon completion of this activity, participants will be able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of mutations and other molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the different approved and investigational targeted therapies for advanced NSCLC in different patient populations, Integrate best practices related to molecular testing through the continuum of advanced NSCLC and interpretation of results to guide treatment selection, Implement evidence-based, individualized, precision treatment plans for patients with advanced NSCLC based on results of molecular testing.


share







 2020-06-08  1h2m